The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies

Jane E. Norman; Harry C. Schouten; Peter Dreger; Stephen P. Robinson

doi:10.1038/s41409-018-0372-5

The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies

Jane E. Norman^*, Harry C. Schouten, Peter Dreger, Stephen P. Robinson

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

Patients with relapsed follicular lymphoma (FL) following first-line therapy have an increasing number of management strategies ranging from observation through to stem cell transplantation. There has been an exciting expansion in novel agents to treat FL, but at present there is not a universally accepted standard of care in the relapse setting. Decision-making can be difficult for the clinician as there is a paucity of data to compare the various relapse therapies available. This review will discuss conventional therapy for relapsed FL, consider the use of novel agents and explore the role and timing of autologous and allogeneic stem cell transplantation.

Original language	English
Pages (from-to)	787-797
Number of pages	11
Journal	Bone Marrow Transplantation
Volume	54
Issue number	6
DOIs	https://doi.org/10.1038/s41409-018-0372-5
Publication status	Published - Jun 2019

Keywords

NON-HODGKIN-LYMPHOMA
TERM-FOLLOW-UP
BONE-MARROW-TRANSPLANTATION
PROGRESSION-FREE SURVIVAL
HIGH-DOSE THERAPY
CHRONIC LYMPHOCYTIC-LEUKEMIA
CHIMERIC-ANTIGEN-RECEPTOR
LOW-GRADE
OPEN-LABEL
PHASE-II

Access to Document

10.1038/s41409-018-0372-5

Cite this

@article{c3e7aa3526ff48428d671b6d93504ca7,

title = "The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies",

abstract = "Patients with relapsed follicular lymphoma (FL) following first-line therapy have an increasing number of management strategies ranging from observation through to stem cell transplantation. There has been an exciting expansion in novel agents to treat FL, but at present there is not a universally accepted standard of care in the relapse setting. Decision-making can be difficult for the clinician as there is a paucity of data to compare the various relapse therapies available. This review will discuss conventional therapy for relapsed FL, consider the use of novel agents and explore the role and timing of autologous and allogeneic stem cell transplantation.",

keywords = "NON-HODGKIN-LYMPHOMA, TERM-FOLLOW-UP, BONE-MARROW-TRANSPLANTATION, PROGRESSION-FREE SURVIVAL, HIGH-DOSE THERAPY, CHRONIC LYMPHOCYTIC-LEUKEMIA, CHIMERIC-ANTIGEN-RECEPTOR, LOW-GRADE, OPEN-LABEL, PHASE-II",

author = "Norman, {Jane E.} and Schouten, {Harry C.} and Peter Dreger and Robinson, {Stephen P.}",

note = "Publisher Copyright: {\textcopyright} 2018, Springer Nature Limited.",

year = "2019",

month = jun,

doi = "10.1038/s41409-018-0372-5",

language = "English",

volume = "54",

pages = "787--797",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Springer",

number = "6",

}

TY - JOUR

T1 - The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies

AU - Norman, Jane E.

AU - Schouten, Harry C.

AU - Dreger, Peter

AU - Robinson, Stephen P.

PY - 2019/6

Y1 - 2019/6

N2 - Patients with relapsed follicular lymphoma (FL) following first-line therapy have an increasing number of management strategies ranging from observation through to stem cell transplantation. There has been an exciting expansion in novel agents to treat FL, but at present there is not a universally accepted standard of care in the relapse setting. Decision-making can be difficult for the clinician as there is a paucity of data to compare the various relapse therapies available. This review will discuss conventional therapy for relapsed FL, consider the use of novel agents and explore the role and timing of autologous and allogeneic stem cell transplantation.

AB - Patients with relapsed follicular lymphoma (FL) following first-line therapy have an increasing number of management strategies ranging from observation through to stem cell transplantation. There has been an exciting expansion in novel agents to treat FL, but at present there is not a universally accepted standard of care in the relapse setting. Decision-making can be difficult for the clinician as there is a paucity of data to compare the various relapse therapies available. This review will discuss conventional therapy for relapsed FL, consider the use of novel agents and explore the role and timing of autologous and allogeneic stem cell transplantation.

KW - NON-HODGKIN-LYMPHOMA

KW - TERM-FOLLOW-UP

KW - BONE-MARROW-TRANSPLANTATION

KW - PROGRESSION-FREE SURVIVAL

KW - HIGH-DOSE THERAPY

KW - CHRONIC LYMPHOCYTIC-LEUKEMIA

KW - CHIMERIC-ANTIGEN-RECEPTOR

KW - LOW-GRADE

KW - OPEN-LABEL

KW - PHASE-II

U2 - 10.1038/s41409-018-0372-5

DO - 10.1038/s41409-018-0372-5

M3 - (Systematic) Review article

SN - 0268-3369

VL - 54

SP - 787

EP - 797

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 6

ER -

The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies

Abstract

Keywords

Access to Document

Fingerprint

Cite this